Process development for pandemic influenza VLP vaccine production using a baculovirus expression system

Adjuvant solution for pandemic influenza vaccine production.

Extensive preparation is underway to mitigate the next pandemic influenza outbreak. New vaccine technologies intended to supplant egg-based production methods are being developed, with recombinant hemagglutinin (rHA) as the most advanced program for preventing seasonal and avian H5N1 Influenza. Increased efforts are being focused on adjuvants that can broaden vaccine immunogenicity against emer...

Preparation and Expression of M2 Gene Plasmid DNA for Potential use in Influenza A Vaccine Production

No abstract this article: Preparation and Expression of M2 Gene Plasmid DNA for Potential use in Influenza A Vaccine Production

A paradigm shift in vaccine production for pandemic influenza.

Virus-like particle (VLP)-based vaccines for pandemic influenza

The influenza pandemic of 2009 demonstrated the inability of the established global capacity for egg-based vaccine production technology to provide sufficient vaccine for the population in a timely fashion. Several alternative technologies for developing influenza vaccines have been proposed, among which non-replicating virus-like particles (VLPs) represent an attractive option because of their...

Development of a new candidate H5N1 avian influenza virus for pre‐pandemic vaccine production

BACKGROUND Highly pathogenic H5N1 avian influenza viruses currently circulating in birds have caused hundreds of human infections, and pose a significant pandemic threat. Vaccines are a major component of the public health preparedness for this likely event. The rapid evolution of H5N1 viruses has resulted in the emergence of multiple clades with distinct antigenic characteristics that require ...